These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31210419)

  • 1. Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.
    Yan C; Wang J; Yang Y; Ma W; Chen X
    J Cell Mol Med; 2019 Aug; 23(8):4876-4882. PubMed ID: 31210419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.
    Schneider K; Weyerbrock A; Doostkam S; Plate K; Machein MR
    J Neurooncol; 2015 Jan; 121(2):269-78. PubMed ID: 25370707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cilengitide treatment for malignant glioma: current status and future direction.
    Kurozumi K; Ichikawa T; Onishi M; Fujii K; Date I
    Neurol Med Chir (Tokyo); 2012; 52(8):539-47. PubMed ID: 22976135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic approaches to malignant gliomas.
    Soffietti R; Trevisan E; Bertero L; Bosa C; Ruda R
    Curr Cancer Drug Targets; 2012 Mar; 12(3):279-88. PubMed ID: 22229250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adhesion molecules and the extracellular matrix as drug targets for glioma.
    Shimizu T; Kurozumi K; Ishida J; Ichikawa T; Date I
    Brain Tumor Pathol; 2016 Apr; 33(2):97-106. PubMed ID: 26992378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature.
    Lombardi G; Zustovich F; Farina P; Polo V; Farina M; Della Puppa A; Bertorelle R; Gardiman MP; Berti F; Zagonel V
    Anticancer Drugs; 2012 Aug; 23(7):749-53. PubMed ID: 22382388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of anti-angiogenic therapy for malignant glioma.
    Reardon DA; Desjardins A; Rich JN; Vredenburgh JJ
    Curr Treat Options Oncol; 2008 Feb; 9(1):1-22. PubMed ID: 18256938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.
    Tamura R; Tanaka T; Miyake K; Yoshida K; Sasaki H
    Brain Tumor Pathol; 2017 Apr; 34(2):62-77. PubMed ID: 28386777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
    Winkler F; Osswald M; Wick W
    Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].
    Tabatabai G; Stupp R
    Nervenarzt; 2010 Aug; 81(8):936-9. PubMed ID: 20669004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapy in malignant glioma: promise and challenge.
    Sathornsumetee S; Rich JN
    Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
    Onishi M; Kurozumi K; Ichikawa T; Date I
    Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells.
    Mesti T; Bouchemal N; Banissi C; Triba MN; Marbeuf-Gueye C; Cemazar M; Moyec LL; Carpentier AF; Savarin P; Ocvirk J
    Radiol Oncol; 2018 Nov; 52(4):392-398. PubMed ID: 30511933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis in malignant glioma--a target for antitumor therapy?
    Tuettenberg J; Friedel C; Vajkoczy P
    Crit Rev Oncol Hematol; 2006 Sep; 59(3):181-93. PubMed ID: 16860996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of FABP7 as a Potential Biomarker for Predicting Prognosis and Antiangiogenic Drug Efficacy of Glioma.
    Hou L; Zhou H; Wang Y; Liu J; Zhang D; Li Y; Xue X
    Dis Markers; 2022; 2022():2091791. PubMed ID: 35783014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy.
    Chung C; Jalali S; Foltz W; Burrell K; Wildgoose P; Lindsay P; Graves C; Camphausen K; Milosevic M; Jaffray D; Zadeh G; Ménard C
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):805-12. PubMed ID: 22929856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.